MyPeBS presentation

MyPeBS (My Personal Breast Screening) is a clinical trial designed to assess the interest in individualized screening based on personal risk of developing breast cancer.

The trial is expected to last 6 years and will recruit 85,000 women aged 40 to 70 (30,000 in Italy, 20,000 in France, 15,000 in Israel, 10,000 in Belgium and 10,000 in the United Kingdom).

These 85,000 women will be randomly assigned to one of two groups :

• The first group (standard screening group) will be required to take part in screening as it is currently organized (in France, no screening before the age of 50, and then a mammogram every two years after the age of 50)
• The second group (individualized screening group) will be required to participate in a screening program whose modalities will be individually adapted to the level of risk of developing breast cancer.
  For women in this second group, a risk score will be calculated based on age, personal and family history, breast density, and a saliva test (genotyping).
  Based on this score, each woman is assigned to one of four risk categories: low risk, moderate risk, high risk, or very high risk.
  Low risk women will not have screening. Moderate risk women will be required to have a mammogram every 2 years (regardless of age). High risk women will be required to have a mammogram every year. Very high risk women will be required to have a mammogram + MRI every year.

The effectiveness of screening will be assessed on the incidence of advanced breast cancer (stage 2 or higher).
The goal of screening is to diagnose breast cancers earlier and therefore at a less advanced stage. If individualized risk screening is more effective than standard screening, the incidence of advanced cancers should be lower in the individualized screening group than in the standard screening group.

The study's proponents hope that individualized screening is more effective than standard screening, but they are not certain. Therefore, they have planned a 2-stage analysis strategy :
- Step 1 = primary objective = demonstrate "non-inferiority" of individualized screening compared with standard screening
- Step 2 = secondary objective = if "non-inferiority" is confirmed, demonstrate the superiority of individualized screening over standard screening.

Other objectives include: comparing false positive rates, comparing over-diagnosis rates, comparing interval cancer rates, assessing costs and comparing cost-effectiveness, etc.

Learn more :
Download the official presentation document of MyPeBS (pdf document, size 2Mb)
Download the synopsis of the MyPeBS study (pdf document, size 1Mb)

---

Dernière mise à jour le 12/09/2021